Please login to the form below

Not currently logged in
Email:
Password:

Zogenix appoints Pfizer’s R Scott Shively as chief commercial officer

Was VP global commercial disease area lead for pain at Pfizer

Pain specialist Zogenix has appointed former Pfizer VP R Scott Shively as its new chief commercial officer.

Shively has experience in the therapy area, serving as VP global commercial disease area lead for pain at Pfizer, and we will have responsibility for all of Zogenix' commercial strategies and operations.

This includes ensuring the success of current products, such as Sumavel DosePro for migraine, as well as soon to be launched products, such as Zohydro, which is pending FDA approval for the treatment of chronic pain.

“We have the potential of launching a new product, expanding our commercial organisation and pursuing a range of corporate development opportunities," said Roger Hawley, CEO of Zogenix.

"Scott's commercial expertise will add important depth and breadth to our executive team. He understands our vision as well as the challenges and opportunities we face.”

Prior to his most recent role at Pfizer, Shively spend a year at the US pharma firm as VP, global commercial medicine team leader.

Other previous positions include senior VP commercial operations at pain specialists Alpharma Pharmaceuticals, VP marketing at Endo Pharmaceuticals and VP global strategy and commercial development at Mallinckrodt.

He said: “I believe my experience, not only in the pain market but also with partnering opportunities and successfully building brands, will provide benefits now and into the next phase of the company's growth. It's an exciting time to join and to make a contribution to the ongoing success of Zogenix."

28th November 2012

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....